WuXi Biologics (Cayman)MEX:2269N 99 Gross Margin % is 48.71% as of Dec. 2025, which is 18% above its 10-year median of 41.31. GuruFocus rates MEX:2269N with a GF Score™ of 99/100 and a GF Value™ of MXN72.14. The stock has 3 warning signs investors should review. Among 737 Biotechnology companies, WuXi Biologics (Cayman) ranks worse than 63.77% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
WuXi Biologics (Cayman) had a gross margin of 48.71% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
WuXi Biologics (Cayman) Gross Margin % Related Terms
WuXi Biologics (Cayman) Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:2269N vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Gross Margin % distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
WuXi Biologics (Cayman) (MEX:2269N) has a Gross Margin % of 48.71% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on WuXi Biologics (Cayman) and its competitors. This is 18% above median its historical median of 41.31. Over the past decade, WuXi Biologics (Cayman)'s Gross Margin % has ranged from 39.34 to 46.93. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #470 out of 737 companies in the Biotechnology industry, placing it in the top 63.8%.
Is WuXi Biologics (Cayman)'s Gross Margin % too high?
WuXi Biologics (Cayman)'s current Gross Margin % of 48.71% is 18% above median its 10-year median of 41.31. Over the past 10 years, this metric has ranged from a low of 39.34 to a high of 46.93. The Biotechnology industry median Gross Margin % is 60.92. WuXi Biologics (Cayman)'s value of 48.71% is 20% below this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #470 out of 737 companies in the Biotechnology industry, which is below the industry midpoint. Overall, WuXi Biologics (Cayman) has a GF Score™ of 99/100, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #470 out of 737 companies for Gross Margin %. This places WuXi Biologics (Cayman) in the lower half of its industry. The industry median Gross Margin % is 60.92. WuXi Biologics (Cayman)'s value of 48.71% is 20% below this benchmark. Historically, WuXi Biologics (Cayman)'s own Gross Margin % has ranged from 39.34 to 46.93 over the past decade. While the company's 10-year median is 41.31 vs. the industry median of 60.92, WuXi Biologics (Cayman) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current Gross Margin % of 48.71% is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current Gross Margin % is 48.71%, which is 18% above median its own 10-year median of 41.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
WuXi Biologics (Cayman) (MEX:2269N) has a current Gross Margin % of 48.71%. The stock's GF Value™ is MXN72.14, compared to a current price of MXN62.53 — trading 13.3% below its estimated fair value. The current Gross Margin % is 48.71%, which is 18% above median its 10-year median of 41.31 and 20% below the Biotechnology industry median of 60.92. WuXi Biologics (Cayman)'s overall GF Score™ is 99/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For WuXi Biologics (Cayman) (MEX:2269N), the current Gross Margin % is 48.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (MEX:2269N) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of MXN62.53 is trading 13.3% below its estimated GF Value™ of MXN72.14.
Key valuation signals for MEX:2269N:
Gross Margin %: 48.71% (18% above median its 10-year median of 41.31)
GF Value™: MXN72.14 vs. price of MXN62.53 (13.3% below fair value)
Industry Position: 20% below the Biotechnology median (#470 of 737)
No single metric tells the full story. See the MEX:2269N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
99GF Score
Get the complete analysis for MEX:2269N
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:2269N has been successfully added to your 
